Multiple randomized trials and meta-analyses exist, but results differ by indication. Alzheimer trials show some short-term cognitive/global signals, whereas the 2023 Cochrane stroke review found no mortality benefit and a potential increase in non-fatal serious adverse events.
Regulatory status
Regulatory availability varies by country; it is not an FDA-approved cognitive enhancer. Jurisdiction-specific product status must be checked separately.
Main limitations
Use for cognitive enhancement in healthy people, consistent benefit across stroke populations, and equivalence of non-authenticated products are not established.
Safety
Safety conclusions differ by clinical setting; acute-stroke Cochrane data raise concern about non-fatal serious adverse events.
i
Multiple randomized trials and meta-analyses exist, but results differ by indication. Alzheimer trials show some short-term cognitive/global signals, whereas the 2023 Cochrane stroke review found no mortality benefit and a potential increase in non-fatal serious adverse events.
What the evidence actually supports
✓Present as mixed/indication-specific evidence, not 'proven nootropic'.
✓This is a key negative/safety finding and should be prominent.
✓Interesting but low-certainty clinical signal.
What is not established / key limitations
×Longer-term cognitive endpoint not consistently significant; older trial set and potential conflicts require caution.
×Potential increase in non-fatal serious adverse events: RR 2.39 in pooled analysis.
×Very small sample and multiple outcomes; requires replication.
Selected study & evidence records
Cerebrolysin for acute ischaemic stroke — Cochrane review
Short-term cognitive and global signals favoured Cerebrolysin; cognitive effect at 6 months was not statistically significant while global change remained significant.
Safety conclusions differ by clinical setting; acute-stroke Cochrane data raise concern about non-fatal serious adverse events.
Safety varies by population and indication. Cochrane stroke evidence found a possible increase in non-fatal serious adverse events despite little/no difference in total serious adverse events.
Technical details
Mechanism / biologyProposed neurotrophic and neuroprotective effects are attributed to a complex mixture of peptides/amino acids; no single active peptide explains the clinical product.
Route / formulation boundaryEvidence applies to a specific biologic mixture formulation, commonly administered intravenously in trials; generic 'peptide blends' are not equivalent.
Identity / data-quality noteTreat as a defined peptide/amino-acid mixture, not a single peptide.
Dosing evidence statusMultiple human trial regimens verified. Published studies commonly used 30 mL/day IV in specific Alzheimer, stroke and TBI protocols; these are study/product regimens, not healthy-person enhancement guidance.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
